Turner Sara

Final Pr. ID: Poster #: EDU-017 (T)

The goal of this presentation is to provide a review of the important role Dual Energy X-ray Absorptiometry (DXA) plays in treating pediatric patients with low bone density. It also aims to educate on the different DXA machines used today, give a review of the official positions for pediatric DXA scans determined by the International Society for Clinical Densitometry (ISCD), give a brief history of the lateral distal femur (LDF) scan and why it was developed, and touch on the other modalities that can be used to asses bone density..

Osteoporosis is commonly thought of as an adult bone health issue; however recently it has gained more attention as being an issue for pediatric patients. Different factors affect bone health, such as genetics and family history, diet and exercise, certain medications, and whether a patient is ambulatory or non-ambulatory. It is important to conduct the proper testing to determine a patient’s fracture risk and trying to prevent further bone deterioration. A DXA Scan is the gold standard across all age groups in providing vital bone health information as it provides a look into the body with minimal radiation exposure to evaluate the bones to determine how much at risk a patient may be. Read More

Authors:  Turner Sara

Keywords:  DXA, Bone Density, Bone Health

Anoni Maria Clara,  Galeano Monica,  Gonseski Vivia Carolina,  Sanchez Salinas Paola

Final Pr. ID: Poster #: EDU-052

Purpose or Case Report: The most common cause of genetic rickets is X-linked hypophosphatemia (XLH) due to an inactivating mutation in the phosphate-regulating neutral endopeptidase X-linked (PHEX) gene. This mutation leads to elevated fibroblast growth factor 23 (FGF23) concentrations and renal phosphate wasting, which causes hypophosphatemic rickets and osteomalacia. Children with rickets often exhibit leg deformities, poor growth, and disproportionate short stature. The primary treatment goal is to correct or at least improve rickets/osteomalacia based on clinical and biochemical parameters.
The conventional treatment for patients with XLH consists of oral supplements of inorganic phosphate salts combined with active vitamin D, but in some patients, adherence is poor. There is a new, promising human monoclonal antibody called burosumab. This treatment specifically targets the excessive activity of XLH by improving renal phosphate reabsorption and promoting intestinal phosphate absorption through the stimulation of 1,25-dihydroxyvitamin D production. Thus, enhancing phosphate homeostasis in these children, burosumab increases serum phosphate levels, alleviating symptoms, and leading to a reduction in skeletal and muscular complications. The purpose of this article is to assess the radiographic images of 7 patients with congenital rickets under treatment with borusumab, using the Rickets Severity Score (RSS). Read More

Authors:  Anoni Maria Clara , Galeano Monica , Gonseski Vivia Carolina , Sanchez Salinas Paola

Keywords:  Pediatric, Bone Density, X-Ray